Secukinumab for Giant Cell Arteritis - PubMed
4 hours ago
- #Clinical Trial
- #Secukinumab
- #Giant Cell Arteritis
- Secukinumab, a monoclonal antibody inhibiting interleukin-17A, was studied as add-on therapy for giant cell arteritis (GCA).
- The GCAptAIN phase 3 trial compared secukinumab doses (300 mg and 150 mg) with placebo, using different glucocorticoid taper schedules.
- At week 52, sustained remission rates were 25.6% for secukinumab 300 mg vs. 16.9% for placebo, and 19.4% for secukinumab 150 mg vs. 17.7% for placebo, with no significant differences.
- Adverse events were common across all groups (92.9–97.4%), with serious adverse events ranging from 20.0% to 32.2%.
- The study concluded that secukinumab did not significantly improve sustained remission compared to placebo when combined with glucocorticoid tapers.